CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy
- 5 March 2015
- journal article
- research article
- Published by Elsevier in Genetics in Medicine
- Vol. 17 (11) , 912-918
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERTPLOS ONE, 2013
- Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe diseaseGenetics in Medicine, 2012
- Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe diseaseGenetics in Medicine, 2012
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe diseaseGenetics in Medicine, 2011
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe DiseasePediatric Research, 2009
- Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe diseaseGenetics in Medicine, 2009
- Elimination of Antibodies to Recombinant Enzyme in Pompe's DiseaseNew England Journal of Medicine, 2009
- Recombinant human acid α-glucosidaseNeurology, 2007
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006